

ABSTRACT

**OSTEOGENESIS ENHANCEMENT BY COMBINATION OF HYDROXY
APATITE AND ELLAGIC ACID APPLIED ON BONE DEFECT
(STUDY ON RAT *RATTUS NOVERGICUS*)**

Agung Satria Wardhana

Background: Bone defect diseases have a high prevalence in Indonesia. Most common therapy for bone defect is bone graft. The graft will initiate osteogenesis on the defect area. Study has prove that phenol compound, as antioxydant and antiinflammation agent, can increase bone formation in bone defect. Current research indicate that Ellagic acid, a phenolic anti-oxidant, have a benefit in healing of bone and wound. Combination between hidroxy apatite and EA is expected to increase osteogenesis process. Osteogenesis can be determined with some mollecular expression, such as osteocalcin, receptor activator nuclear kappa B ligand (RANKL) and osteoprotegerin (OPG). The purpose of this research is to analyze bone defect's osteogenesis after application of combination of hidroxy apatite and 3% ellagic acid through the expression of osteocalcin, RANKL, OPG, osteoblast and osteoclast. **Method:** This is a true experimental research using post-test only with control group design. Our subjects are 30 wistar rats with bone dfect made in left femur, devided in six groups. Each group consist of five rats and divided as: (1) Negative control. Bone defect treated with polyethylene glycol, (2) Positive control treated with hidroxy apatite, and (3) group treated with combination of hidroxy apatite and ellagic acid. The subject sacrificed in day seven and 14. **Result:** The result shown in treatment group, when compared to control groups, have a significant increase of osteocalcin and OPG expressions ($P<0.05$), otherwie the expression of RANKL and osteoclast significantly decrease ($P<0.05$). **Conclusion:** Group with ellagic acid combination show enhancement of osteocalcin, OPG and osteoblas expression, and lower the expression of RANKL and osteoclast.

Keywords: Osteogenesis, hidroxy apatite, ellagic acid, osteocalcin, RANKL, OPG.

DAFTAR ISI

HALAMAN SAMPUL DALAM	ii
LEMBAR PENGESAHAN	Error! Bookmark not defined.
PENETAPAN PANITIA PENGUJI TESIS	iii
PERNYATAAN ORISINALITAS	v
UCAPAN TERIMA KASIH.....	vi
ABSTRAK	viii
<i>ABSTRACT</i>	ix
DAFTAR ISI.....	x
DAFTAR TABEL.....	xv
DAFTAR GAMBAR	xvi
DAFTAR SINGKATAN	xvii
BAB 1. PENDAHULUAN	1
1.1. Latar Belakang Masalah	1
1.2. Rumusan Masalah.....	5
1.3. Tujuan Penelitian	5
1.3.1. Tujuan Umum	5

1.3.2. Tujuan Khusus	5
1.4. Manfaat Penelitian	5
1.4.1. Manfaat Teoritis.....	5
1.4.2. Manfaat Praktis	6
BAB 2. TINJAUAN PUSTAKA	7
2.1. Tulang	7
2.1.1. Definisi Tulang	7
2.1.2. Struktur Tulang	7
2.2. Remodeling Tulang.....	10
2.3. Osteokalsin	14
2.4. <i>Reseptor Activator of Nuclear Factor-Kappaβ Ligand</i> (RANKL)....	15
2.5. <i>Ellagic Acid</i>	16
2.6. Hidroksi Apatit	18
2.7. <i>Rattus Novergicus</i> Strain Wistar.....	20
2.8. Imunohistokimia	21
BAB 3. KERANGKA KONSEP DAN HIPOTESIS PENELITIAN	23
3.1. Kerangka Konseptual Penelitian.....	23

3.2. Hipotesis Penelitian	25
BAB 4. METODOLOGI PENELITIAN.....	26
4.1. Jenis dan Rancangan Penelitian.....	26
4.2. Populasi, Besar Sampel dan Teknik Pengambilan Sampel.....	27
4.2.1. Populasi.....	27
4.2.2. Teknik Penghitungan Sampel	27
4.2.3. Besar Sampel	28
4.3. Variabel Penelitian.....	28
4.3.1. Variabel Bebas	28
4.3.2. Variabel Terikat	28
4.3.3. Variabel Terkendali	28
4.3.4. Definisi Operasional	29
4.4. Bahan Penelitian	30
4.4.1. Bahan untuk pembuatan defek tulang pada tikus	30
4.4.2. Bahan untuk perlakuan	30
4.4.3. Bahan untuk pemeriksaan imunohistokimia.....	30
4.5. Instrumen Penelitian	31

4.5.1.	Instrumen untuk pembuatan jejas pada tikus.....	31
4.5.2.	Instrumen untuk perlakuan	32
4.5.3.	Instrumen untuk pemeriksaan laboratorium	32
4.6.	Lokasi dan Waktu Penelitian	32
4.6.1.	Lokasi Penelitian.....	32
4.6.2.	Waktu Penelitian.....	32
4.7.	Prosedur Penelitian dan Pengumpulan Data.....	32
4.7.1.	Perijinan Ethical clearance.....	32
4.7.2.	Pengelompokan Hewan Coba.....	33
4.7.3.	Pembuatan HA dan kombinasi HA + EA	33
4.7.4.	Pembuatan Luka pada hewan coba.....	33
4.7.5.	Pengorbanan dan pengambilan jaringan	34
4.7.6.	Pembuatan Sediaan	34
4.7.7.	Teknik Pengecatan Imunohistokimia dan Penghitungan.....	37
4.7.8.	Penanganan Bangkai Hewan Coba.....	38
4.8.	Bagan Alur Operasional Penelitian.....	39
4.9.	Analisis Data.....	40

BAB 5. HASIL PENELITIAN	41
5.1. Hasil Penelitian.....	41
5.1.1. Uji Imunohistokimia.....	41
5.1.2. Perhitungan Jumlah Osteoblas dan Osteoklas	45
5.2. Analisis hasil penelitian.....	47
BAB 6. PEMBAHASAN.....	54
BAB 7. KESIMPULAN DAN SARAN	61
7.1. Kesimpulan	61
7.2. Saran	61
DAFTAR PUSTAKA	62
LAMPIRAN-LAMPIRAN.....	67

DAFTAR TABEL

	Halaman
Tabel 5.1 Ekspresi Osteokalsin.....	42
Tabel 5.2 Ekspresi RANKL.....	43
Tabel 5.3 Ekspresi OPG	45
Tabel 5.4 Ekspresi Osteoblas.....	46
Tabel 5.5 Ekspresi Osteoklas.....	47
Tabel 5.6 Rerata ekspresi Osteokalsin, RANKL, OPG.....	48
Tabel 5.7 Rerata jumlah osteoblas dan osteoklas	48
Tabel 5.8 Hasil uji normalitas data	49
Tabel 5.9 Hasil uji homogenitas data	49
Tabel 5.10 Hasil Uji post-hoc LSD Osteokalsin	50
Tabel 5.11 Hasil Uji post-hoc LSD RANKL	51
Tabel 5.12 Hasil Uji post-hoc LSD OPG	51
Tabel 5.13 Hasil Uji post-hoc LSD Osteoblas	52
Tabel 5.14 Hasil Uji post-hoc LSD Osteolas	53

DAFTAR GAMBAR

	Halaman
Gambar 2.1 Proses penyembuhan tulang.....	11
Gambar 2.2 Struktur kimia ellagic acid.....	16
Gambar 2.3 Struktur kimia hidroksi apatit.....	18
Gambar 3.1 Kerangka konsep penelitian	23
Bagan 4.1 Bagan Rencana Penelitian	25
Gambar 4.1 Alur Penelitian	39
Gambar 5.1 Ekspresi Osteokalsin	42
Gambar 5.2 Ekspresi RANKL	43
Gambar 5.3 Ekspresi OPG	44
Gambar 5.4 Ekspresi Osteoblas dan Osteoklas	46

DAFTAR SINGKATAN

HA	: Hidroksi Apatit
EA	: Ellagic acid
RANKL	: <i>Receptor Activator of Nuclear Factor Kappa β Ligand</i>
OPG	: Osteoprotegerin
OPN	: Osteopontin
CFU	: Colony Formation Unit
CFU-F	: Colony Formation Unit Fibrosit
CFU-GM	: Colony Formation Unit Granulosit Makrofag
TGF- β	: Transforming Growth Factor
TNF	: Tumor Necrose Factor
OPGL	: Osteoprotegerin Ligand
ODF	: Osteoklas <i>Differentiation Factor</i>
TRANCE	: TNF Related Activation Induced Cytokine
RANK	: <i>Receptor Activator of Nuclear Factor Kappa β</i>
M-CSF	: <i>Macrophage Colony Stimulating Factor</i>
PEG	: Poly Ethylene Glycol
RA	: Random Allocation
HE	: Haematoxillyn Eosin
PBS	: Posphate Buffer saline
DMSO	: <i>Dimethyl sulfoxide</i>
EDTA	: Ethylene Diamine Tetra Acetil Acid
BHK-21	: Baby Hamster Kidney